DCT

1:25-cv-01260

Bayer Healthcare Pharma Inc v. Zydus Lifesciences Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:25-cv-01260, D. Del., 10/15/2025
  • Venue Allegations: Plaintiff alleges venue is proper in Delaware for Zydus Lifesciences (a foreign corporation) based on personal jurisdiction, and for Zydus Pharmaceuticals (USA) based on anticipated acts of infringement in the state upon ANDA approval. The complaint further alleges personal jurisdiction over both defendants due to systematic business contacts, sales in Delaware, and prior consent to jurisdiction in the district.
  • Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the drug KERENDIA® (finerenone) constitutes an act of infringement of a patent covering a specific crystalline form of finerenone and methods of its preparation.
  • Technical Context: The lawsuit is in the field of pharmaceutical chemistry, concerning a patented process for manufacturing and purifying a specific stable crystalline form of an active pharmaceutical ingredient, finerenone.
  • Key Procedural History: The patent-in-suit, RE49,826, is a reissue of U.S. Patent No. 10,336,749. Reissue proceedings can create arguments regarding the scope of the claims and intervening rights, although the complaint does not allege any such defense has been raised. The litigation was triggered by Zydus's Paragraph IV certification notice, a formal act under the Hatch-Waxman Act declaring its belief that the patent is invalid or will not be infringed by its generic product.

Case Timeline

Date Event
2015-08-21 RE'826 Patent Priority Date
2019-07-02 Original U.S. Patent No. 10,336,749 Issues
2021-07-09 FDA Approves Bayer's New Drug Application for KERENDIA®
2024-02-06 U.S. Reissue Patent No. RE49,826 Issues
2025-09-04 Zydus sends Paragraph IV Notice Letter to Bayer
2025-09-05 Bayer receives Paragraph IV Notice Letter
2025-10-15 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

  • Patent Identification: U.S. Reissue Patent No. RE49,826, Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient, issued February 6, 2024.

The Invention Explained

  • Problem Addressed: The patent's background states that prior "research scale synthesis" methods for the compound finerenone were unsuitable for large-scale industrial production. These methods suffered from issues including high dilution, the use of excessive reagents, low overall yield, and a reliance on numerous costly and laborious chromatographic purifications '826 Patent, col. 1:45-58
  • The Patented Solution: The patent discloses an "industrially practicable synthesis" that produces the finerenone compound in high yield and purity '826 Patent, col. 1:59-65 The improved process proceeds through a different series of chemical reactions than the prior art research method and, crucially, includes a final crystallization step that reproducibly yields a specific, stable crystalline form designated "polymorph I" '826 Patent, col. 13:54-61 '826 Patent, col. 14:1-24 This specific polymorph is described as having very good stability properties, which is important for pharmaceutical formulation and storage '826 Patent, col. 15:27-31
  • Technical Importance: The invention provides a reproducible, scalable, and economically viable manufacturing process for a defined, stable crystalline form of a pharmaceutical, a critical requirement for obtaining regulatory approval and ensuring consistent product quality in commercial drug production '826 Patent, col. 1:59-65

Key Claims at a Glance

  • The complaint asserts infringement of "one or more claims" of the RE'826 Patent without specifying them Compl. ¶55 Based on the nature of an ANDA case concerning a final drug product, independent claim 14, which covers the specific crystalline form of the compound, is a likely focus.
  • Independent Claim 14:
    • A compound of the formula (I) in crystalline form of polymorph I
    • wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 8.5, 14.1, and 19.0.
  • The complaint does not explicitly reserve the right to assert dependent claims, but this is standard practice in patent litigation.

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Zydus's proposed generic finerenone tablets in 10 mg and 20 mg dosages, as described in ANDA No. 220636 Compl. ¶1 Compl. ¶43

Functionality and Market Context

The accused product is a generic version of Bayer's branded drug, KERENDIA® Compl. ¶1 Finerenone, the active ingredient, is a non-steroidal mineralocorticoid receptor antagonist (nsMRA) indicated for reducing risks associated with chronic kidney disease in patients with type 2 diabetes, as well as for certain heart failure conditions Compl. ¶34 Zydus seeks FDA approval to market its generic version before the expiration of the RE'826 Patent Compl. ¶1

IV. Analysis of Infringement Allegations

The complaint does not include a claim chart or provide a detailed, element-by-element infringement analysis. The central allegation is that the submission of ANDA No. 220636, which seeks approval to market a generic version of KERENDIA®, constitutes a technical act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶53 The infringement theory is that the product described in the ANDA will, upon manufacture and sale, meet the limitations of one or more claims of the RE'826 Patent. Below is a summary chart based on this theory for representative product claim 14.

No probative visual evidence provided in complaint.

RE'826 Patent Infringement Allegations

Claim Element (from Independent Claim 14) Alleged Infringing Functionality Complaint Citation Patent Citation
A compound of the formula (I) in crystalline form of polymorph I... The complaint alleges that Zydus's ANDA seeks approval to market a generic version of Bayer's finerenone drug product. Finerenone is the compound of formula (I). The infringement allegation implicitly requires that Zydus's product contains this compound in the claimed "polymorph I" form. ¶1; ¶43; ¶55 col. 14:45-48
wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 8.5, 14.1, and 19.0. The complaint alleges that Zydus's submission of its ANDA for a generic finerenone product infringes the RE'826 Patent. The basis for infringement is that the product described in the ANDA will possess the structural characteristics defined by the patent's claims, including these specific XRD peaks. ¶53; ¶55 col. 56:64-67
  • Identified Points of Contention:
    • Structural Questions: The primary question will be factual: does the active pharmaceutical ingredient in the product described in Zydus's ANDA exist in the "crystalline form of polymorph I"? This will likely involve a battle of experts analyzing spectroscopic and crystallographic data of Zydus's proposed product.
    • Scope Questions: A central legal question may concern the proper interpretation of "polymorph I." Does the term, as used in claim 14, only require the presence of the three recited X-ray diffraction peaks, or must an accused product exhibit the full range of characteristics (e.g., additional peaks, IR bands, Raman bands) described for Polymorph I in the patent's specification '826 Patent, col. 42:20-65 '826 Patent, col. 14:59-65?

V. Key Claim Terms for Construction

  • The Term: "crystalline form of polymorph I"
  • Context and Importance: This term is the central limitation of the primary product claim (Claim 14). The outcome of the infringement analysis for this claim will depend entirely on whether Zydus's product is determined to be this specific polymorph. Practitioners may focus on this term because its definition dictates the boundary between infringing and non-infringing crystalline forms of finerenone.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party seeking a broader construction (likely Bayer) may argue that the plain language of claim 14 defines the polymorph by the presence of three specific XRD peaks at 8.5, 14.1, and 19.0 '826 Patent, claim 14 The principle of claim differentiation may be invoked, as dependent claim 15 adds further peak limitations, suggesting that claim 14 is not limited by those additional peaks '826 Patent, claim 15
    • Evidence for a Narrower Interpretation: A party seeking a narrower construction (likely Zydus) may argue that "polymorph I" is defined by the entirety of its characteristics as disclosed in the specification. This includes a much more extensive list of XRD peaks '826 Patent, col. 42:20-65, specific IR band maxima '826 Patent, col. 14:59-65, Raman band maxima '826 Patent, col. 15:20-24, and a specific melting point '826 Patent, col. 15:17-19 This party could argue that the specification's repeated and detailed description of "polymorph I" acts as a lexicographical definition, limiting the claim to a form that matches this complete fingerprint.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon approval of its ANDA, Zydus will actively induce infringement by health care professionals and patients who use the generic product in accordance with its label Compl. ¶64 It also alleges contributory infringement, stating Zydus's product is not a staple article suitable for substantial non-infringing use Compl. ¶57
  • Willful Infringement: The complaint alleges that Zydus has "full knowledge of the RE'826 Patent," a basis for willfulness arising from the act of filing a Paragraph IV certification Compl. ¶57 Bayer also requests that the court declare the case "exceptional" and award attorneys' fees under 35 U.S.C. § 285 Compl. ¶67 Compl., Prayer H

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of structural identity: As an evidentiary matter, does the crystalline form of the finerenone active ingredient in Zydus's proposed generic product meet the structural definition of "polymorph I" as claimed in the patent? The case will likely depend on competing expert analyses of crystallographic data.
  • A second central issue will be one of definitional scope: How will the court construe the term "crystalline form of polymorph I"? Will it be defined broadly by the three X-ray diffraction peaks explicitly recited in claim 14, or will it be limited more narrowly to a form that must also exhibit the full set of detailed physical and spectroscopic characteristics described in the patent's specification?
  • A final question relates to validity and non-infringement of process claims: Zydus's Paragraph IV letter explicitly challenges the validity and asserts non-infringement of several process claims Compl. ¶45 Should Bayer press these claims, the case will also turn on whether Zydus's manufacturing process reads on the patented method and whether those process claims can withstand Zydus's obviousness challenges.
Loading Complaint